Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care 'test-and-treat' strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol

Kate Beard, Nathan Brendish, Ahalya Malachira, Samuel Mills, Cathleen Chan, Stephen Poole, Tristan Clark, Kate Beard, Nathan Brendish, Ahalya Malachira, Samuel Mills, Cathleen Chan, Stephen Poole, Tristan Clark

Abstract

Background: Influenza infections often remain undiagnosed in patients admitted to hospital due to lack of routine testing. When tested for, the diagnosis and treatment of influenza are often delayed due to the slow turnaround times of centralised laboratory PCR testing. Newer molecular systems, have comparable accuracy to laboratory PCR testing, and can generate a result in under 1 hour, making them potentially deployable as point-of-care tests (POCTs). High-quality evidence for the impact of routine POCT for influenza on clinical outcomes is, however, currently lacking. This large pragmatic multicentre randomised controlled trial aims to address this evidence gap.

Methods and analysis: The FluPOC trial is a pragmatic, multicentre, randomised controlled trial evaluating adults admitted to a large teaching hospital and a district general hospital with an acute respiratory illness, during influenza season and defined by Public Health England. Up to 840 patients will be recruited over up to three influenza seasons, and randomised (1:1) to receive either POCT using the FilmArray respiratory panel, or routine clinical care. Clinical and infection control teams will be informed of the results in real time and where influenza is detected clinical teams will be encouraged to offer neuraminidase inhibitor (NAI) treatment in accordance with national guidelines. Those allocated to standard clinical care will have a swab taken for later analysis to allow assessment of missed diagnoses. The outcomes assessment will be by retrospective case note analysis. The outcome measures include the proportion of influenza-positive patients detected and appropriately treated with NAIs, isolation facility use, antibiotic use, length of hospital stay, complications and mortality.

Ethics and dissemination: Prior to commencing the study, approval was obtained from the South Central Hampshire A Ethics Committee (reference 17/SC/0368, granted 7 September 2017). Results generated from this protocol will be published in peer-reviewed scientific journals and presented at national and international conferences.

Trial registration number: ISRCTN17197293.

Keywords: adult; hospitalised; influenza; neuraminidase inhibitors; point-of-care test.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Participant flow through the study. NAI, neuraminidase inhibitor; NIHR WTCRF, National Institute for Health Research Wellcome Trust Clinical Research Facility; POCT, point-of-care test.

References

    1. Lozano R, Naghavi M, Foreman K, et al. . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128. 10.1016/S0140-6736(12)61728-0
    1. Clark TW, Medina M-jo, Batham S, et al. . Adults hospitalised with acute respiratory illness rarely have detectable bacteria in the absence of COPD or pneumonia; viral infection predominates in a large prospective UK sample. J Infect 2014;69:507–15. 10.1016/j.jinf.2014.07.023
    1. Thompson WW, Shay DK, Weintraub E, et al. . Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179–86. 10.1001/jama.289.2.179
    1. Thompson WW, Shay DK, Weintraub E, et al. . Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333–40. 10.1001/jama.292.11.1333
    1. Irwin DE, Weatherby LB, Huang WY, et al. . Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res 2001;1:8 10.1186/1472-6963-1-8
    1. van den Dool C, Hak E, Wallinga J, et al. . Symptoms of influenza virus infection in hospitalized patients. Infect Control Hosp Epidemiol 2008;29:314–9. 10.1086/529211
    1. Babcock HM, Merz LR, Dubberke ER, et al. . Case-control study of clinical features of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2008;29:921–6. 10.1086/590663
    1. Babcock HM, Merz LR, Fraser VJ. Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2006;27:266–70. 10.1086/501539
    1. Call SA, Vollenweider MA, Hornung CA, et al. . Does this patient have influenza? JAMA 2005;293:987–97. 10.1001/jama.293.8.987
    1. Falsey AR, Hennessey PA, Formica MA, et al. . Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352:1749–59. 10.1056/NEJMoa043951
    1. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009;9:601–10. 10.1016/S1473-3099(09)70233-6
    1. Schanzer DL, Schwartz B. Impact of seasonal and pandemic influenza on emergency department visits, 2003-2010, Ontario, Canada. Acad Emerg Med 2013;20:388–97. 10.1111/acem.12111
    1. López Roa P, Rodríguez-Sánchez B, Catalán P, et al. . Diagnosis of influenza in intensive care units: lower respiratory tract samples are better than nose-throat swabs. Am J Respir Crit Care Med 2012;186:929–30. 10.1164/ajrccm.186.9.929
    1. Falsey AR, Formica MA, Walsh EE. Yield of sputum for viral detection by reverse transcriptase PCR in adults hospitalized with respiratory illness. J Clin Microbiol 2012;50:21–4. 10.1128/JCM.05841-11
    1. Public Health England PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza (version 6.0, 2015.
    1. Muthuri SG, Venkatesan S, Myles PR, et al. . Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014;2:395–404. 10.1016/S2213-2600(14)70041-4
    1. Katzen J, Kohn R, Houk JL, et al. . Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes. Clin Infect Dis 2019;69:52–8. 10.1093/cid/ciy860
    1. Centers for Disease Control and Prevention (CDC) Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) Virus - United States, 2009. MMWR Morb Mortal Wkly Rep 2009;58:826–9.
    1. Chartrand C, Leeflang MMG, Minion J, et al. . Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 2012;156:500–11. 10.7326/0003-4819-156-7-201204030-00403
    1. Nicholson KG, Abrams KR, Batham S, et al. . Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds. Health Technol Assess 2014;18:1e274 10.3310/hta18360
    1. Mackay IM. Real-time PCR in the microbiology laboratory. Clin Microbiol Infect 2004;10:190–212. 10.1111/j.1198-743X.2004.00722.x
    1. Biofire diagnostics. FilmArray® respiratory panel.
    1. Popowitch EB, O'Neill SS, Miller MB. Comparison of the BioFire FilmArray RP, GenMark eSensor RVP, Luminex xTAG RVPv1, and Luminex xTAG RVP fast multiplex assays for detection of respiratory viruses. J Clin Microbiol 2013;51:1528–33. 10.1128/JCM.03368-12
    1. Poritz MA, Blaschke AJ, Byington CL, et al. . Filmarray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection. PLoS One 2011;6:e26047 10.1371/journal.pone.0026047
    1. Butt SA, Maceira VP, McCallen ME, et al. . Comparison of three commercial RT-PCR systems for the detection of respiratory viruses. J Clin Virol 2014;61:406–10. 10.1016/j.jcv.2014.08.010
    1. Pierce VM, Elkan M, Leet M, et al. . Comparison of the Idaho technology FilmArray system to real-time PCR for detection of respiratory pathogens in children. J Clin Microbiol 2012;50:364–71. 10.1128/JCM.05996-11
    1. Loeffelholz MJ, Pong DL, Pyles RB, et al. . Comparison of the FilmArray respiratory panel and Prodesse real-time PCR assays for detection of respiratory pathogens. J Clin Microbiol 2011;49:4083–8. 10.1128/JCM.05010-11
    1. Ruggiero P, McMillen T, Tang Y-W, et al. . Evaluation of the BioFire FilmArray respiratory panel and the GenMark eSensor respiratory viral panel on lower respiratory tract specimens. J Clin Microbiol 2014;52:288–90. 10.1128/JCM.02787-13
    1. Hammond SP, Gagne LS, Stock SR, et al. . Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods. J Clin Microbiol 2012;50:3216–21. 10.1128/JCM.00538-12
    1. Doern CD, Lacey D, Huang R, et al. . Evaluation and implementation of FilmArray version 1.7 for improved detection of adenovirus respiratory tract infection. J Clin Microbiol 2013;51:4036–9. 10.1128/JCM.02546-13
    1. Branche AR, Walsh EE, Vargas R, et al. . Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. J Infect Dis 2015;212:1692–700. 10.1093/infdis/jiv252
    1. Dugas AF, Valsamakis A, Atreya MR, et al. . Clinical diagnosis of influenza in the ED. Am J Emerg Med 2015;33:770–5. 10.1016/j.ajem.2015.03.008
    1. Brendish NJ, Malachira AK, Armstrong L, et al. . Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med 2017;5:401–11. 10.1016/S2213-2600(17)30120-0
    1. Legand A, Briand S, Shindo N, et al. . Addressing the public health burden of respiratory viruses: the battle against respiratory viruses (brave) initiative. Future Virol 2013;8:953–68. 10.2217/fvl.13.85
    1. O’Neil J. Tackling drug-resistant infections globally: final report and recommendations, 2016.
    1. WHO Fact sheet: antimicrobial resistance. Available: [Accessed 4 May 2019].
    1. Chan A-W, Tetzlaff JM, Altman DG, et al. . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7. 10.7326/0003-4819-158-3-201302050-00583
    1. Halm EA, Fine MJ, Marrie TJ, et al. . Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279:1452–7. 10.1001/jama.279.18.1452
    1. Schulz KF, Altman DG, Moher D, et al. . Consort 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010;8:18 10.1186/1741-7015-8-18
    1. Jakobsen JC, Gluud C, Wetterslev J, et al. . When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol 2017;17:162 10.1186/s12874-017-0442-1

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe